In a landmark step for experimental medicine, a patient in Ohio received an injection of a virus whose design was generated by artificial intelligence, marking the inaugural use of an AI‑created therapeutic in a human trial.
The AI‑Designed Phage Therapy
The treatment was administered through a specialised access programme that permits clinicians to trial investigational therapies when standard options are exhausted.
The patient, whose identity has not been disclosed, was treated with a cocktail of bacteriophages whose genetic blueprints were produced by Radical Numerics’ AI system, Omnii-1.
Omnii-1 reengineered portions of a viral genome so that the resulting phage could recognise and bind to the specific bacterial strain causing the infection, a process the company claims could be completed within days rather than months.
Before the clinical application, the AI‑generated viruses were tested against a sample taken from the patient; laboratory assays showed that the mixture eradicated the antibiotic‑resistant bacteria in vitro.
The company has not yet released data on the patient’s clinical outcome or whether the infection was fully cleared.
Context and Biosafety Concerns
Earlier in August, researchers at Stanford University and the Arc Institute announced that they had synthesised and tested nearly 300 AI‑designed viral genomes, with 16 of them yielding functional phages capable of killing E. coli in laboratory conditions.
Those experiments were conducted entirely in microbial cultures, not in humans, and the findings have not yet been peer‑reviewed.
Scientists have warned that the ability of AI to fabricate novel viral sequences raises significant biosafety questions, especially if the technology were to be applied to pathogens that infect people or animals.
While the Stanford team deliberately focused on bacteriophages that target bacteria rather than human cells, experts are calling for stronger regulatory safeguards as AI‑driven biological research accelerates.
Future Outlook
Radical Numerics believes its AI platform can streamline the development of personalised phage therapies, offering a faster route to treatment for patients with life‑threatening, drug‑resistant infections.
The company plans to pursue further clinical trials, aiming to generate robust, peer‑reviewed evidence on safety and efficacy.
Why it Matters
This breakthrough illustrates how artificial intelligence can reshape medical practice by rapidly producing tailored therapies for conditions that evade conventional antibiotics, potentially saving lives while also demanding vigilant oversight to prevent misuse of a technology capable of designing new pathogens.
